Remission in Adults With Mild-to-moderate Asthma in Thailand
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 289
- 试验地点
- 2
- 主要终点
- Prevalence rate of mild-to-moderate asthma remission
研究概览
简要总结
The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.
详细描述
This study is a cross-sectional study. Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).
GINA and ACT are questionnaires used to assess the level of asthma control.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •mild-to-moderate asthma
- •age 18 years or older
排除标准
- •inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test
研究组 & 干预措施
Mild-to-moderate asthma
Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms <3 times per week, have preserved lung function (FEV₁ or PEF >80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications.
Moderate asthma refers to asthma patients who have symptoms >4-5 days per week or experience nocturnal asthma symptoms >1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.
干预措施: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires (Other)
Mild-to-moderate asthma
Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms <3 times per week, have preserved lung function (FEV₁ or PEF >80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications.
Moderate asthma refers to asthma patients who have symptoms >4-5 days per week or experience nocturnal asthma symptoms >1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.
干预措施: Spirometry (Other)
Mild-to-moderate asthma
Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms <3 times per week, have preserved lung function (FEV₁ or PEF >80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications.
Moderate asthma refers to asthma patients who have symptoms >4-5 days per week or experience nocturnal asthma symptoms >1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.
干预措施: Fractional exhaled nitric oxide (FeNO) test (Other)
Mild-to-moderate asthma
Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms <3 times per week, have preserved lung function (FEV₁ or PEF >80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications.
Moderate asthma refers to asthma patients who have symptoms >4-5 days per week or experience nocturnal asthma symptoms >1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.
干预措施: Blood eosinophil count (BEC) (Other)
结局指标
主要结局
Prevalence rate of mild-to-moderate asthma remission
时间窗: An average of 1 year
Prevalence rate of mild-to-moderate asthma remission (%)
次要结局
- Asthma control in patients with mild-to-moderate asthma(At baseline and at 12 months)
- Airway obstruction in patients with mild-to-moderate asthma(At baseline and at 12 months)
- Severity of aiway obstruction in patients with mild-to-moderate asthma(At baseline and at 12 months)
- Eosinophil airway inflammation in patients with mild-to-moderate asthma(At baseline and at 12 months)
- Type 2 airway inflammation in patients with mild-to-moderate asthma(At baseline and at 12 months)
研究者
Narongkorn Saiphoklang, MD
Associate Professsor
Thammasat University